Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 19, 2024British Journal of Haematology

Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis

View Full Paper
Ask AI
Bookmark
Share

Authors

VKVivekanudeep KarriHLHoward LinJVJessica Velazquez

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Karri et al. (2024) studied this question.

synapsesocial.com/papers/68e73509b6db6435876aedaahttps://doi.org/10.1111/bjh.19380
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms2022 · 4,224 citations
  2. 2CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH‐associated neurodegeneration and mass lesions2018 · 137 citations
  3. 3Dabrafenib, alone or in combination with trametinib, in <i>BRAF</i> V600–mutated pediatric Langerhans cell histiocytosis2023 · 52 citations
  4. 4<i>BRAF-V600E</i> expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups2014 · 445 citations
  5. 5Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas2017 · 104 citations